PNC-28
Based on 1 Customer Validation
PNC-28 is a peptide from the mdm-2-binding domain (residues 17–26) of the p53 protein which contains a membrane crossing-penetratin sequence. PNC-28 can be used for pancreatic cancer research.
For research use only. We do not sell to patients.
- Purity : 98.20%
- CAS No.: 392661-17-5
- Formula: C164H255N47O37S
- Molecular Weight:3509.13
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
PNC-28 (0-0.5 mg/mL) blocks growth of a lethal human pancreatic cancer cell line[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MiaPaCa-2 human pancreatic carcinoma cells
-
Concentration:0.1, 0.3, and 0.5 mg/mL
-
Incubation Time:daily
-
Result:Showed dependent induction of tumor cell death starting at 0.1 mg/ml.
In Vivo
PNC-28 (1-20 mg/mouse, SC, for 14 days) inhibits BMRPA1. Tuc3 tumor growth especially if delivered directly to the tumor [1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Athymic Nu/Nu mice (7–8 weeks, 22–24 g, injected i.p. with BMRPA1.Tuc3 cells)[1]
-
Dosage:2 mg/mouse
-
Administration:Implanted s.c. or i.p., with 14 days mini-osmotic pumps releasing PNC-28 at a rate of 0.25 μl/hr
-
Result:No ascites was seen in the PNC-28-treated animals. strongly effective in inhibiting this particular tumor.
-
Animal Model:Athymic Nu/Nu mice (7–8 weeks, 22–24 g, injected i.p. with BMRPA1.Tuc3 cells)[1]
-
Dosage:1 mg/mouse, 10 mg/mouse and 20 mg/mouse
-
Administration:When the tumors reached sizes from 40 to 260 mg/mouse, mini-osmotic pumps were implanted s.c. that released, over a period of 14 days
-
Result:Resulted in a significant level of tumor growth inhibition in a dose-related manner.
Chemical Information
-
CAS No. 392661-17-5
-
Appearance Solid
-
Molecular Weight 3509.13
-
Formula C164H255N47O37S
-
Color White to off-white
-
Sequence Shortening
ETFSDLWKLLKKWKMRRNQFWVKVQRG
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
In Vitro:
H2O : 25 mg/mL (7.12 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Primary monocyte-to-macrophage differentiation
Primary human monocytes can be differentiated ex vivo into monocyte-derived macrophages by culturing purified blood monocytes for approximately 5-7 days in macrophage-supporting cytokine conditions; M-CSF commonly yields CD14^high/CD163^high macrophages, while GM-CSF yields a phenotypically distinct macrophage population, so the cytokine condition should be chosen according to the downstream model. The readout of successful differentiation is a combined change in morphology, adherence, surface phenotype, and function: differentiated macrophages become adherent, enlarge, acquire macrophage-associated markers such as CD14, CD68, CD163, CD206, or HLA-DR depending on culture condition, and show increased phagocytic capacity compared with starting monocytes.
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 0.2850 mL | 1.4249 mL | 2.8497 mL | 7.1243 mL |
| 5 mM | 0.0570 mL | 0.2850 mL | 0.5699 mL | 1.4249 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
PNC-28 Related Classifications
HY-P3509 Related Classifications
Powered by Bioz